AURA BIOSCIENCES INC (AURA)
US05153U1079 - Common Stock
Multiple Clinical Complete Responses Demonstrated Following Single Low Dose Administration of Bel-sar in Patients with Non-Muscle-Invasive Bladder Cancer (NMIBC) in Ongoing Phase 1 Trial
Clinical Complete Responses Observed in 4 out of 5 Patients in Subset of Patients with Low Grade Disease; Evidence of Bladder Urothelial Field Effect in...
Aura Biosciences Reports Positive Phase 2 End of Study Results Evaluating Bel-sar as a First-Line Treatment for Early-Stage Choroidal Melanoma
Bel-sar Demonstrated 80% Tumor Control Rate, 90% Visual Acuity Preservation, and a Highly Favorable Safety Profile Aura to Host a Virtual Ocular Oncology...
Aura Biosciences to Host a Urologic Oncology Investor Event to Present Early Non-Muscle Invasive Bladder Cancer (NMIBC) Data from its Ongoing Phase 1 Trial on Thursday, October 17, 2024
Sabine Doris Brookman-May, MD, PhD to join Aura as Senior Vice President, Clinical Development Urologic Oncology...
Aura Biosciences Shares Cross Above 200 DMA
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision therapies to...
Aura Biosciences Announces the Presentation of Phase 2 End of Study Data Evaluating Suprachoroidal Administration of Bel-sar for the First-Line Treatment of Patients with Early-Stage Choroidal Melanoma at The Retina Society Annual Meeting
Aura will Host a Virtual Ocular Oncology Investor Event Featuring Key Opinion Leaders at 8:00 am Eastern Time on September 12, 2024...
Commit To Buy Aura Biosciences At $5, Earn 13.6% Annualized Using Options
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the second quarter of 2024.
AURA Stock Earnings: Aura Biosciences Beats EPS for Q2 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aura Biosciences (NASDAQ:AURA) just reported results for the second quarter of ...
Aura Biosciences Reports Second Quarter 2024 Financial Results and Business Highlights
Company to Present Early Non-muscle Invasive Bladder Cancer (NMIBC) Data from Ongoing Phase 1 Trial at a Urologic Oncology Investor Event in October 2024 ...
Bullish Two Hundred Day Moving Average Cross - AURA
Aura Biosciences to Participate in the Jefferies Global Healthcare Conference
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision...
Aura Biosciences to Host Virtual KOL Event “Pioneering a New Standard of Care In Ocular Oncology” on May 29, 2024
BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision...
Commit To Purchase Aura Biosciences At $5, Earn 12.1% Annualized Using Options
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Aura Biosciences (NASDAQ:AURA) just reported results for the first quarter of 2...
AURA Stock Earnings: Aura Biosciences Beats EPS for Q1 2024
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the first quarter of 2024.
Aura Biosciences Reports First Quarter 2024 Financial Results and Business Highlights
Continued Enrollment in Global Phase 3 CoMpass Trial in Small Choroidal Melanoma and Indeterminate Lesions Ongoing Phase 1 Trial in Bladder Cancer...
Aura Biosciences to Participate in Upcoming Investor Conferences
BOSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Aura Biosciences, Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing precision...
AURA Stock Earnings: Aura Biosciences Beats EPS for Q4 2023
AURA stock results show that Aura Biosciences beat analyst estimates for earnings per share the fourth quarter of 2023.
Aura Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights
Aura Biosciences to Participate in Upcoming Investor Conferences
Commit To Purchase Aura Biosciences At $7.50, Earn 32.6% Annualized Using Options
Investors Grab AURA 11.4% Cheaper Than Its Secondary Stock Offering
Commit To Buy Aura Biosciences At $7.50, Earn 35.9% Annualized Using Options
Friday 11/10 Insider Buying Report: AURA, FARO
Aura Biosciences director David Johnson buys common shares worth ~$1.44M (NASDAQ:AURA)
Aura Biosciences (NASDAQ:AURA) disclosed on Thursday director David Johnson bought ~200K common shares at an average price of $7.24/share for ~$1.44...
Aura Biosciences GAAP EPS of -$0.48 (NASDAQ:AURA)
Aura Biosciences press release (NASDAQ:AURA): Q3 GAAP EPS of -$0.48.As of September 30, 2023, the company had cash and cash equivalents and marketable...
Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights
Investors Snag AURA 18.9% Cheaper Than Its Secondary Stock Offering